See the factory by live video walkthrough
Book an on-site factory visit in Guangzhou
For cosmetic brands, the under-eye area represents both a major consumer concern and a regulatory tightrope. Formulating a product that credibly addresses "dark circles" requires understanding that the condition is rarely a single problem.…
For cosmetic brands, the under-eye area represents both a major consumer concern and a regulatory tightrope. Formulating a product that credibly addresses “dark circles” requires understanding that the condition is rarely a single problem. It's typically a combination of pigmentation, vascular visibility, and structural shadowing. This article breaks down the physiological mechanisms behind under-eye discoloration and outlines an evidence-based strategy to build truthful, non-drug claims that resonate with buyers and withstand scrutiny.
To develop a product with targeted efficacy, you must move beyond the umbrella term “dark circles.” Research and clinical observation show it stems from three main pathways, which often coexist. Your claim strategy must precisely mirror the mechanism your formula is designed to address.
This presents as brown or grey-brown hyperpigmentation, often with a distinct border and irregular distribution, sometimes in a “lacelike” pattern. It's driven by excess melanin production and deposition in the epidermis and upper dermis.
Primary Causes & Targets:
This isn’t a skin color change but an optical shadow. It is deepened by the natural hollow formed by the tear trough ligament, which tethers the thin under-eye skin to the bone. As we age, volume loss in the mid-face fat pads and bone resorption makes this defect more pronounced, creating a dark shadow irrespective of skin quality.
What Topicals Can (and Cannot) Do:
This manifests as blue, purple, or pink tones due to the visibility of the underlying orbicularis oculi muscle and vascular network through exceptionally thin, translucent skin. A compromised capillary network, where hemoglobin leaks into the dermis, is a key pathological component.
Key Targets for Formulation:
Substantiating a multi-functional eye product requires a multi-pronged testing strategy. No single instrument or study type can capture the full picture. A robust plan should combine hypothesis-driven clinical studies with standard safety appraisals.
You cannot rely on subjective grading alone. Instrumentation provides the objective data needed to support performance claims and defend against competitor challenges.
| Symptom & Claim | Recommended Instrument | Key Metric | Data Output |
|---|---|---|---|
| Brownish Pigmentation | Colorimeter / Spectrophotometer | ITA°, Melanin Index, L* (Lightness) | Reduction in melanin, increase in brightness |
| Bluish-Red Discoloration | Colorimeter / Spectrophotometer | a* (redness), Erythema Index, Individual Typology Angle | Reduction in redness, shift toward yellow (degraded hemoglobin) |
| Anatomical Shadowing | Skin Profilometry / Optical Profilometry | Anisotropy, Surface Roughness (Ra, Rz) | Reduction in anisotropy, smoother skin surface |
| Puffiness / Edema | 3D Imaging with Fringe Projection | Volume (mm³), Maximum Protrusion Height | Reduction in max under-eye volume |
Instrumental data must be correlated with expert visual grading using validated ordinal scales to prove the measured change is clinically, not just statistically, significant. A well-designed protocol grades pigmentation intensity, vascularity, and overall shadowing severity. A global improvement score assessed by both the investigator and the subject bridges objective data with perceived cosmetic benefit.
Claims like “instant luminosity,” “awakened look,” and “cooling sensation” are critical for consumer appeal. These are substantiated through immediate-use sensory panels that measure the short-term effect of light-diffusing minerals and film-forming polysaccharides on immediate skin radiance and surface smoothing.
Puffiness is an oscillatory condition, often worse in the morning and subsiding with lymphatic drainage. Poorly designed studies yield null results. Success requires a controlled protocol that induces a baseline “puffiness challenge” (e.g., controlled salt intake and a supine period the night before assessment) to ensure a measurable edema state from which to demonstrate regression after a single product application. 3D fringe projection imaging, measuring volume change, is the gold standard for quantification.
The most significant regulatory risk in eye care is making implied drug or medical device claims. Structures and mechanisms in the tear trough cannot be reconfigured by a cosmetic. Any claim that suggests a cosmetic can rebuild the “scaffold,” “restore lost orbital fat,” or “correct the tear trough” is an unapproved drug claim, particularly in jurisdictions with strict OTC drug boundaries for structure/function. Safe cosmetic territory focuses entirely on the skin's surface: improving radiance, smoothness, and the appearance of skin tone. A claim for a “lifting” or “tightening” film is permissible if it describes a temporary cosmetic effect of a polymer film, not a lasting physiological change.
Yes, a well-formulated product can contain active ingredients targeting melanogenesis (for pigmentation), microcirculation and dermal density (for vascular), and cosmetic diffusers (for shadowing). However, each claim pathway requires its own substantiation. A single clinical study must take multiple distinct endpoints.
Any claim that implies a permanent structural change, such as “fills tear troughs” or “restores lost volume.” Also, rapid-action claims like “erases dark circles in 5 minutes” require robust, statistically significant instrumental data from an immediate-effect study.
An 8-week to 12-week study with endpoints at baseline, 4 weeks, and 8 weeks is standard. For pigmentation, 12 weeks is preferred to observe a meaningful melanin turnover cycle. A separate immediate-effect study is needed for short-term radiance and optical smoothing claims.
Caffeine is widely used for its dehydrating and microcirculatory effect, helpful for temporary puffiness reduction, but evidence for lasting effects on pigmentation is weak. Topical vitamin K has been studied for its role in aiding the clearance of leaked hemoglobin byproducts, showing promise for vascular dark circles, though formulations must ensure stability and penetration. Both need to be supported by formula-specific testing.
This was addressed earlier—you must design a study that creates controlled conditions to induce a measurable puffiness baseline stage the night before the test day. The product’s effect is then measured as a reduction from that induced baseline. Fringe projection imaging to quantify volume change provides the concrete data needed.
Developing a successful and defensible under-eye product requires a fusion of nuanced formulation science and a meticulously planned evidence strategy. By precisely defining your target mechanism—whether pigmentation, vascularity, or shadowing—and matching it with robust clinical instrumentation, you build a product that performs and a brand story that lasts.
Take the first step toward substantiating your next hero eye product. Request a Quote to discuss your concept, timelines, and testing requirements with our R&D team.
With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.
